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Anna Y. Kucheryavaya, MS, Christian Benden, MD, Anne I. Dipchand, MD, FRCPC,
Fabienne Dobbels, PhD, Richard Kirk, MA, FRCP, FRCPCH, Lars H. Lund, MD, PhD,
Axel O. Rahmel, MD, and Josef Stehlik, MD, MPH; for the International Society for Heart
and Lung TransplantationFrom the ISHLT Transplant Registry, Dallas, Texas.This section of the 30th official Registry report of 2013
summarizes data from 43,428 adult lung and 3,703 adult
heart-lung transplant recipients and their donors for trans-
plants that occurred through June 30, 2012. This report
describes donor and recipient characteristics, transplant
type, and recipient outcomes data. The full Registry slide set
available online (www.ishlt.org/registries) provides more
detail, additional analyses, and other information not
included in this printed report. For the first time, the
Registry report focuses on an overall theme of recipient and
donor age and incorporates new age-related analyses into its
annual update.Data collection and statistical methods
Standard statistical methods were used for analyses and
reporting. Where appropriate, a more detailed explanation
about the analytical methodology accompanies the Web site
slides (in the “Notes Page” view).
The Kaplan-Meier method was used for assessing time-
to-event rates (eg, survival). Survival graphs (ie, time-to-
event graphs) were truncated when the number of
analyzable individuals fell below 10. Censoring occurred
at the time a patient was last reported to be alive (eg, mostt matter Published by Elsevier Inc.
16/j.healun.2013.08.007
ef.stehlik@hsc.utah.edu
osef Stehlik, MD, MPH, University of Utah Health
ision of Cardiology, U.T.A.H. Cardiac Transplant
cal Dr, 4A100 SOM, Salt Lake City, UT 84132.
340. Fax: 801-581-7735.recent annual follow-up) and at the time of retransplantation
for analyses that focus on the first transplant. The survival
analyses provided patient median survival (where possible)
as the estimated time at which 50% of all recipients
died. Conditional analyses only included those patients
who met the required criterion (eg, survival past 1 year
post-transplant). The log-rank test was used to compare
survival curves among groups. Cox proportional hazards
regression was used for multivariable time-to-event
analyses. The Cox models calculated hazard ratios (HR),
corresponding 95% confidence intervals (CIs), and p-values.
A HR of 1 suggests that the factor (eg, bilateral vs unilateral
lung transplantation) is not associated with the event
(eg, mortality). A HR 4 1.0 suggests that presence
of the factor is associated with a higher probability
of the event studied (ie, the group exposed to the
factor has a higher hazard than the group not exposed),
whereas a HR o 1.0 suggests that the factor is associated
with a lower probability of the event (ie, the group ex-
posed to the factor has a lower hazard than the group not
exposed).
Some analyses incorporated multiple imputations to
estimate missing information for continuous data fields,
such as ischemic time and donor age.1 This method
produced an estimated value for the missing value based
on the other characteristics of the patient, the donor, and/or
the transplant. The combining of model fit on each imputed
data set produced a final set of estimates and associated HR
estimates and p-values. Models may have excluded
variables that lacked statistical significance due to small
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Figure 1 Number of reported adult lung transplants by year and procedure type reported to the International Society for Heart and Lung
Transplantation Registry.
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Figure 2 Number of centers and distribution of adult lung
transplants by center volume (transplants: January 2000—June
2012). Each bar indicates the number of centers for a given average
annual center volume, and each square indicates the percentage of
total transplants by average annual center volume.
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Figure 4 Adult lung transplant recipient age distribution by
era. Each bar represents the proportion of lung transplants from a
given era within a recipient age category.
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that is, a significant association between the variable
and the outcome may have escaped detection even though
it existed.0%
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Figure 3 Age distribution of lung donors for adult recipients by year
represents the proportion of transplants for donor age categories withinSome analyses were adjusted for multiple comparisons (eg,
Scheffe, Bonferroni). For unadjusted analyses (eg, survival
curves of bilateral vs. unilateral lung transplantation), we0
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of transplantation (transplants: January 1987–June 2012). Each bar
a given year, and the diamonds show the median donor age.
Yusen et al. ISHLT 30th Adult Lung and Heart-Lung Transplant Report 967recommend cautious interpretation because the different
groups of interest may have an uneven distribution of
clinical characteristics (eg, recipient age, underlying diag-
nosis, and comorbidities) and other factors (eg, preference
of transplant center and donor lung characteristics) asso-
ciated with the outcome undergoing assessment (eg,
survival). For comparisons of risk among different cohorts
(eg, assessment of age relationship to survival in cohorts
from different eras), cautious interpretation is recommended
for similar reasons. In addition, the models did not adjust for
all of the important known and unknown confounders. Also,
the models may lack generalizability for specific sub-groups
of patients or for specific settings (eg, different organ
allocation systems).
Registry data accuracy depended on center reporting
accuracy. In addition, some of the reporting procedures may
have introduced bias into the data collection process. For
example, a 1-year follow-up form was not completed for
patients who died before transplantation hospital discharge;
thus, events assessed on the 1-year follow-up form were
therefore not reported in this scenario even though they
might have occurred.Lung transplantation
Centers and transplant activity
The Registry now contains data from 42,069 adult recipients
who underwent lung transplantation (including retrans-
plants) before 2012. From 132 participating transplant
centers, the Registry obtained data for 3,640 adult lung
transplantation procedures performed in 2011, which
represented the highest number reported of any year to date
(Figure 1). The increased number of procedures primarily
occurred due to the consistent growth in the number of
bilateral lung transplants since the mid-1990s; the number of
single-lung transplants performed annually during this time
has remained relatively stable.
A total of 177 centers reported at least 1 adult lung
transplant performed between January 2000 and June 2012
(Figure 2). Fifty-two percent of the transplant procedures
were performed at 31 centers (18% of centers) that had an
average activity of 30 or more transplants per year. Seven
centers (4% of centers) had an average activity of 50 or
more transplants per year and performed 20% of the
procedures reported during this period. Eighty-three small-
er-volume centers (47% of centers) averaged fewer than 10
transplants per year and conducted 8% of the lung
transplantations during this period.Donor age
Young adults (age 18–29 years) comprised 30% of donors
in the Registry, whereas only 1% of donors were aged4 65
years (Figure 3). Donors for adult lung recipients during the
first 6 months of 2012 had a median age of 38 years. The
donor age has trended upward during the past 2 decades.
Compared with 2 previous decade eras (1985–1994 and1995–2004), the latest 7.5-year era (January 2005–June
2012) showed an increase in the proportion of 3 categories
of older donors (aged 50–59 years, 60–65 years, and 4 65
years), whereas the proportion of 2 categories of younger
adult donors (aged 18–29 and 30–39 years) decreased.2 The
proportion of donors aged 40 to 49 years remained stable
during over the past 2 eras. Compared with North American
and other centers throughout the world for the era of January
2000 to June 2012, European centers used a greater
proportion of older donors.2Recipient age
Almost 66% of lung transplant recipients were aged 45 to 65
years.2 Since 1985, the median age of recipients gradually
increased from 45 years to 55 years (Figures 4 and 5). From
2006 through mid-2012, 10% of recipients were4 65 years
old and 3% were 4 70 years old compared with 3% and
0.3%, respectively, in 2000 to 2005.2 The increased age of
recipients occurred mainly in the diagnostic groups of
interstitial lung diseases (ILD) and chronic obstructive
pulmonary disease (COPD) exclusive of α1-antitrypsin
deficiency (non-A1ATD COPD).2 For transplants that
occurred January 2000 through June 2012, North American
centers had a higher proportion of recipients with aged 60 to
65 years and 4 65 years than centers in Europe and other
centers throughout the rest of the world.2Donor and recipient age relationships
From January 1985 through June 2012, a very small
proportion of adult lung transplant recipients received
organs from pre-adolescent (ages 0–11 years) pediatric
donors (Figure 6). The proportion of adult recipients that
received organs from adolescent (ages 12–17 years)
pediatric donors hovered around 10%.Indications
For adult lung transplantations that occurred between
January 1995 and June 2012 (Table 1), the most common
primary indications were non-A1ATD COPD (34%),
followed by ILD (24%), bronchiectasis associated with
cystic fibrosis (CF, 17%), and COPD associated with
A1ATD (6%). From 2001 to 2011, the percentage of
recipients with non-A1ATD COPD gradually decreased
from 40% to 30%, and the percentage of transplants for ILD
increased from 17% to 29%.2
Centers reported a diagnosis of retransplantation in 2.6%
of lung recipients. The most common indication for
retransplantation was bronchiolitis obliterans syndrome
(BOS; Table 1). The proportion of recipients aged 18 to
65 years who underwent retransplantation was almost twice
as high as in recipients older than 65 years.
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Figure 5 Adult lung transplant recipient age by year (transplants: January 1987–June 2012). Each bar represents the proportion of
transplants for recipient age categories within a given year, and the diamonds show the median recipient age.
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Although most recipients who had CF or idiopathic
pulmonary arterial hypertension (IPAH) underwent bilateral0%
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Figure 6 Donor and recipient age for adult lung transplantation
(transplants: January 1985–June 2012). Each bar represents the
proportion of donors for each donor age category within a given
recipient age category.
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Figure 7 Adult lung transplantation procedure types according to indica
transplants for each procedure type within a given year. A1ATD, α1-anti
(COPD); COPD, non-A1ATD associated COPD; ILD, interstitial lung distransplantation over the years, a marked change from
unilateral to bilateral transplantation occurred for recipients
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Figure 8 Adult lung transplant recipient Kaplan-Meier survi-
val, stratified by procedure type (transplants: January 1994–June
2011). Conditional median survival for the sub-set of recipients
who were alive 1 year after transplantation.
Table 1 Indications for Adult Lung Transplants Performed January 1995–June 2012
Single lung Bilateral/double lung Total
(n ¼ 14,197) (n ¼ 23,384) (N ¼ 37,581)
Diagnosis No. (%) No. (%) No. (%)
COPD
Without A1ATD 6,312 (44.5) 6,290 (26.9) 12,602 (33.5)
With A1ATD 753 (5.3) 1,429 (6.1) 2,182 (5.8)
Interstitial lung diseasea 4,872 (34.3) 4,032 (17.2) 8,904 (23.7)
Bronchiectasis associated with CF 229 (1.6) 6,002 (25.7) 6,231 (16.6)
IPAH 87 (0.6) 1,073 (4.6) 1,160 (3.1)
Pulmonary fibrosis, other 563 (4.0) 820 (3.5) 1,383 (3.7)
Bronchiectasis 59 (0.4) 956 (4.1) 1,015 (2.7)
Retransplantb
Obliterative bronchiolitis 276 (1.9) 292 (1.2) 568 (1.5)
Not obliterative bronchiolitis 182 (1.3) 220 (0.9) 402 (1.1)
Sarcoidosis 265 (1.9) 689 (2.9) 954 (2.5)
Connective tissue disease 156 (1.1) 332 (1.4) 488 (1.3)
Obliterative bronchiolitis (not retransplant) 98 (0.7) 298 (1.3) 396 (1.1)
Lymphangioleiomyomatosis 136 (1.0) 255 (1.1) 391 (1.0)
Congenital heart disease 56 (0.4) 269 (1.2) 325 (0.9)
Cancer 7 (0.0) 29 (0.1) 36 (0.1)
Other 146 (1.0) 398 (1.7) 544 (1.4)
A1ATD, α1-antitrypsin deficiency; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; IPAH, idiopathic pulmonary arterial hypertension.
aIncludes idiopathic pulmonary fibrosis.
bCombined retransplant data, 970 (2.6%).
Yusen et al. ISHLT 30th Adult Lung and Heart-Lung Transplant Report 969In recent years, most recipients in the top 5 indications for
lung transplantation underwent bilateral procedures.Lung transplant outcomes
Survival
Adults who underwent lung transplantation in the era of
January 1994 through June 2011 had a median survival of
5.6 years (Figure 8), with unadjusted survival rates of 88%
at 3 months, 79% at 1 year, 64% at 3 years, 53% at 5 years,
and 31% at 10 years. Recipients who survived to 1 year after
transplant had a conditional median survival of 7.9 years.
Patients undergoing bilateral lung transplantation had higher
overall and conditional unadjusted survival rates than those
undergoing unilateral lung transplantation. Survival of adult
recipients varied by era (Figure 9). The most recent era
showed better survival than the previous 2 eras, and the
survival curves separated in the early period after transplant:
3-month survival improved between the earliest era and the
most recent era from 81% to 90%, and 1-year survival
improved from 70% to 81%.
Survival also varied by indication for transplantation
(Figure 10). Those with non-A1ATD COPD had the lowest
unadjusted 3-month mortality (9%), whereas those with IPAH
had the highest mortality (22%).2 However, conditional median
survival for patients surviving to 1 year was higher for CF (10.5
years), IPAH (10.0 years), sarcoidosis (8.5 years), and A1ATD
COPD (8.7 years) compared with those with non-A1ATD
COPD (6.9 years) or ILD (7.0 years; Figure 11.
Lung transplant recipient groups stratified by pre-
transplantation cytomegalovirus (CMV) serologic status indonors and recipients had different survival rates (Figure 12).
Transplant recipients who received lungs from CMV-negative
donors had better survival than those who received lungs from
CMV-positive donors.
Survival rates for transplants performed between January
1990 and June 2011differed by recipient age (Figure 13).
For example, recipients older than 65 years had a median
survival of 3.6 years compared with 6.5 years for those aged
35 to 49 years. For the 3 recipient age groups aged older
than 49 years, survival rates worsened with increasing age.
Interestingly, all of the age groups had similar 3-month
survival of 87% to 90%, after which survival rates diverged
and favored the younger age groups: 5-year survival was
38% for recipients aged465 years, 46% for those 60 to 65
years, and 52% to 57% for those younger than 60 years.
Procedure type, era of transplant, age at transplant,
primary indication for transplant, and multiple other factors
each had a significant association with survival rates,
whereas others did not. As noted above, multiple other
factors may have affected survival, and these survival
figures were not fully adjusted for such factors. Some
factors also had significant interactions with others. For
example, age-related survival differences became more
prominent after adjustment for era. Most of the transplants
in older patients occurred in more recent eras, which had
better overall reported survival. Also, significant interactions
occurred between age group and indication for transplant
within the primary lung diagnostic groups of COPD and
ILD (Figure 14). Older recipients within each diagnostic
group had worse overall and conditional survival. When
assessing overall survival, significant interactions also
occurred between age groups and type of transplant (bilateral
vs unilateral) within primary lung diagnostic groups.2
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Figure 9 Adult lung transplant recipient Kaplan-Meier
survival by era (transplants: January 1988–June 2011). Condi-
tional, median survival for the sub-set of recipients who were alive
1-year after transplantation.
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Figure 10 Adult lung transplant recipient Kaplan-Meier
survival by diagnosis (transplants: January 1990–June 2011).
A1ATD, α1-antitrypsin deficiency–associated chronic obstruc-
tive pulmonary disease (COPD); COPD, non-A1ATD associated
COPD; CF, bronchiectasis associated with cystic fibrosis (CF);
ILD, interstitial lung disease, which includes idiopathic pulm-
onary fibrosis (IPF); IPAH, idiopathic pulmonary arterial
hypertension.
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plants: January 1990–June 2011). A1ATD, α1-antitrypsin defi-
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The major reported causes of death (January 1992 through
June 2012) within the first 30 days after transplantation
consisted of graft failure and non-CMV infections (Table 2).
During the remainder of the first year, non-CMV infection
became the most prominent as a cause of death. After the
first post-transplant year, BOS/chronic lung rejection, graft
failure (late deaths coded as “graft failure” may represent
lung rejection or BOS), and non-CMV infection caused0
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COPD 18-49 (N=1,971) ILD 18-49 (N=1,936)
COPD 50-65 (N=10,190) ILD 50-65 (N=5,582)
COPD >65 (N=753) ILD >65 (N=1,010)
Median survival (years):
COPD: 18-49 = 6.4; 50-65 = 5.4; >65 = 3.7
ILD:      18-49 = 5.7; 50-65 = 4.3; >65 = 3.8
All pair-wise comparisons within diagnosis groups 
were significant at p < 0.001 except ILD 50-65 vs. >65.
No pair-wise comparisons within age groups were 
significant at < 0.05 except for 50-65
Figure 14 Adult lung transplant recipient Kaplan-Meier
survival by diagnosis and age group (transplants: January 1990–
June 2011). COPD, chronic obstructive pulmonary disease not
associated with α1-antitrypsin deficiency; ILD, interstitial lung
disease, which includes idiopathic pulmonary fibrosis (IPF).
Yusen et al. ISHLT 30th Adult Lung and Heart-Lung Transplant Report 971most deaths. Not long after transplant, malignancy became a
significant contributor to mortality.Risk factors for death
Risk factors for death were evaluated using multivariable
Cox models. For transplants performed between January
1999 and June 2011, categoric factors that showed an
independent association with risk of death during the first
post-transplant year, after adjustment for other factors in the
model, included era of transplant, type of underlying lung
disease of the recipient, retransplantation, the severity of
recipient illness at the time of transplantation, recipient age,
and transplant center volume (Table 3). Specifically, prior
era, more severe illness, advanced age, and low transplant
center volume showed an independent association with risk
of death. Donor variables played a small role. As described
in the statistical methods section, we recommend cautious
interpretation of these models.
The increased risk of 1-year mortality with older
recipient age began at approximately 55 years and rose
exponentially thereafter (Figure 15). An increased risk of
1-year mortality became apparent when transplant center
volume fell below 30 transplants per year (Figure 16).
Analyses of 1-year mortality performed within models for
diagnosis categories of non-A1ATD COPD and ILD yielded
mostly similar results.2 Age remained a significant risk
factor in those models. In addition, male gender became a
risk factor in the non-A1ATD COPD model.
The 5-year mortality risk factors were similar to those
associated with 1-year mortality risk.2 However, for this
analysis, unilateral lung transplantation for ILD (compared
with unilateral lung transplantation for non-A1ATD COPD)
and extremes of recipient age (Figure 15) conferred an
independent risk of death at 5 years after transplant.Table 2 Causes of Deaths for Adult Lung Transplant Recipients (Dea
Cause of Death
0-30 days 31 days–1 year 41–
(n ¼ 2,725) (n ¼ 4,737) (n ¼
No. (%)a No. (%)a No. (
Bronchiolitis 8 (0.3) 216 (4.6) 1,119
Acute rejection 94 (3.4) 85 (1.8) 63
Malignancy
Lymphoma 1 (0.0) 110 (2.3) 78
Non-lymphoma 5 (0.2) 134 (2.8) 329
Infection
CMV 0 112 (2.4) 42
Non-CMV 535 (19.6) 1,687 (35.6) 971
Graft failureb 672 (24.7) 790 (16.7) 807
Cardiovascular 298 (10.9) 228 (4.8) 179
Technical 301 (11.0) 162 (3.4) 38
Other 811 (29.8) 1,213 (25.6) 689
aPercentages refer to deaths in the respective time period.
bSome misclassification may occur among the cause of death terms of bronch
reporting, may represent acute rejection, primary graft dysfunction, or other ca
causes late after transplant.Risk factors for 5-year mortality, conditional on survival
to 1 year, showed some changes in the diagnostic categories
(indications for lung transplant) that were included in the
unconditional 5-year survival analysis.2 For this conditional
analysis, compared with the 1-year and 5-year non-condi-
tional survival analyses, the diagnosis of retransplantation
was no longer associated with risk of death. The conditional
analysis also showed that recipients with BOS or acute
rejection in the first year after transplant had a higher risk of
death at 5 years. Similar to the non-conditional 5-year
mortality risk model, the conditional model demonstrated
that extremes of recipient age conferred an independent risk
of higher mortality (Figure 15), and the risk in the younger
adult recipients became more prominent. Lower transplant
center volume again had a negative effect on longer-term
survival, even when examining outcomes in the patients
who survived to 1 year after transplant. This finding
suggests that programmatic differences associated with
transplant volume exist beyond those related to the trans-
plant procedure.
Risk factors for 10-year mortality were mostly similar to
those identified in the other models. Again, extremes of
recipient age conferred an independent risk (Figure 15).
Interestingly, for this model, donor age showed an
independent association with mortality. The risk of death
was increased in recipients of lungs from donors older than
30 years.Acute and chronic lung rejection
According to data compiled between July 2004 and June
2012, 33% of adult lung recipients experienced at least
1 episode of acute rejection between discharge and the
1-year follow-up (Figure 17). The youngest adult age
category (age 18–34 years) had slightly higher incidence ofths: January 1992–June 2012)
3 years 43–5 years 45–10 years 410 years
4,315) (n ¼ 2,449) (n ¼ 2,892) (n ¼ 899)
%)a No. (%)a No. (%)a No. (%)a
(25.9) 710 (29.0) 734 (25.4) 188 (20.9)
(1.5) 16 (0.7) 17 (0.6) 2 (0.2)
(1.8) 36 (1.5) 56 (1.9) 31 (3.4)
(7.6) 266 (10.9) 379 (13.1) 113 (12.6)
(1.0) 7 (0.3) 4 (0.1) 1 (0.1)
(22.5) 471 (19.2) 523 (18.1) 154 (17.1)
(18.7) 440 (18.0) 515 (17.8) 156 (17.4)
(4.1) 120 (4.9) 148 (5.1) 58 (6.5)
(0.9) 14 (0.6) 24 (0.8) 8 (0.9)
(16.0) 369 (15.1) 492 (17.0) 188 (20.9)
iolitis, acute rejection, and graft failure. Graft failure, due to variation in
uses early after transplant, or bronchiolitis obliterans syndrome or other
Table 3 Risk Factors From Time of Transplant for 1-Year Mortality in Adult Lung Transplant Recipients (Transplants: January 1999–June
2011; N ¼ 15,822)
Category Variable No. HR (95% CI)a p-valuea
Diagnosisb Retransplant 585 1.69 (1.38–2.07) o.0001
Connective tissue disease 297 1.36 (1.04–(1.76) 0.0226
Other 787 1.32 (1.10–1.60) 0.0035
Lymphangioleiomyomatosis 129 0.47 (0.24–0.93) 0.0289
Transplant characteristics Transplant year
1999/2000 vs 2010/2011 1,655 2.23 (1.92–2.60) o.0001
2001/2002 vs. 2010/2011 2,030 1.82 (1.56–2.11) o.0001
2003/2004 vs. 2010/2011 2,188 1.39 (1.19–1.62) o.0001
2005/2006 vs. 2010/2011 2,753 1.37 (1.19–1.57) o.0001
2007/2008 vs. 2010/2011 2,903 1.25 (1.09–1.43) 0.001
Donor CMVþ/ recipient CMV– 3,416 1.17 (1.07–(1.28) 0.0007
Donor characteristics History of diabetes 764 1.43 (1.21–1.68) o.0001
Recipient characteristics Dialysis 79 1.92 (1.34–2.75) 0.0004
Hospitalized (including ICU) 1,984 1.7 (1.51–1.91) o.0001
Ventilator 737 1.53 (1.30–1.79) o.0001
Prior transfusion 802 1.18 (1.01–1.38) 0.037
Borderline significant Pulmonary embolism 135 1.32 (0.95–1.83) 0.0928
Diagnosis
IPAH 375 1.31 (0.99–1.72) 0.0571
Sarcoidosis, double lung 365 1.27 (0.98–1.64) 0.0673
COPD with A1ATD 708 1.25 (0.98–1.59) 0.0750
COPD without A1ATD, single lung 2,867 0.85 (0.71–1.03) 0.0921
Chronic steroid use 7,562 1.07 (0.99–1.16 0.0765
Continuous characteristics Recipient age o.0001
Transplant center volume o.0001
Bilirubin 0.0085
Recipient oxygen required at rest 0.0001
Cardiac output 0.0001
Donor-recipient height difference 0.0032
Recipient FVC %predicted 0.0018
PaCO2 0.0096
A1ATD, α1-antitrypsin deficiency; CI, confidence interval; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; FVC, forced vital
capacity; HR, hazard ratio; ICU, intensive care unit; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; PaCO2, partial pressure
of arterial carbon dioxide.
aCalculated using Cox proportional hazard model.
bReference group¼ ILD. Other ¼ all diagnoses other than COPD without A1ATD, IPAH, ILD, cystic fibrosis, pulmonary fibrosis, bronchiectasis, COPD with
A1ATD, retransplant, lymphangioleiomyomatosis, and connective tissue disease.
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categories.
BOS, conditioned on surviving to 2 weeks after trans-
plant to avoid biases introduced by early death, remained a
common long-term complication, as determined by follow-
up assessments performed between April 1994 and June
2012 (Figure 18). Within 5 years of transplantation, 49% of
recipients developed BOS, and 76% developed BOS by 10
years post-transplant. Freedom from BOS did not appear to
vary much according to age group, indication for transplant,
or induction immunosuppression use.2
Complications and morbidities
Morbidities commonly caused or exacerbated by immuno-
suppressive medicines (eg, hypertension, renal dysfunction,
diabetes, and hyperlipidemia) occurred frequently after lung
transplantation (Table 4). Within the first year after trans-
plantation, recipients aged 4 65 years had similar rates ofhypertension, diabetes, renal dysfunction, acute rejection,
and BOS compared with younger adults.2 However, the
older group had a higher rate of hyperlipidemia.
The complication rates rose significantly over time.2 Of
note, recipients had a high incidence of severe renal
dysfunction. Within 5 years after transplantation, 24% of
recipients experienced creatinine 4 2.5 mg/dl, dialysis, or
renal transplant, and 41% experienced any of these
complications within 10 years. Older age groups had higher
rates of severe renal dysfunction over long-term follow-up
than younger age groups.
Cancer rates increased over time after lung trans-
plantation.2 At least 1 malignancy was reported for 21%
of recipients at 5 years post-transplantation and for 40% at
10 years post-transplantation. Skin cancer had the highest
incidence of all cancers, although post-transplant lympho-
proliferative disease remained an important morbid con-
dition. Recipients aged 4 65 years had higher rates of skin
cancer over long-term follow-up than younger recipients.
Table 4 Cumulative Morbidity Rates in Adult Lung Transplant Survivors Within 1 and 5 Years After Transplant (Follow-ups: April 1994–
June 2012)
Outcome
Within 1 year Total with known response Within 5 years Total with known response
(%) (No.) (%) (No.)
Hypertension 51.7 15,267 82.4 4,503
Renal dysfunction 23.3 17,291 55.4 5,571
Abnormal creatinine o 2.5 mg/dl 16.2 36.5
Creatinine 4 2.5 mg/dl 5.2 15.0
Chronic dialysis 1.7 3.2
Renal transplant 0.1 0.7
Hyperlipidemia 25.5 15,975 58.4 4,856
Diabetes 24.6 17,227 40.5 5,498
Bronchiolitis obliterans syndrome 9.5 16,264 39.7 4,701
Table 5 Indications for Adult Heart-Lung Transplants
Performed January 1982–June 2012
Diagnosis
No. (%)
(N ¼ 3,241)
Congenital heart disease 1,154 (35.6)
Idiopathic pulmonary arterial hypertension 890 (27.5)
Cystic fibrosis 453 (14.0)
Acquired heart disease 165 (5.1)
COPD without A1ATD 136 (4.2)
Interstitial lung diseases 119 (3.7)
Retransplant 59 (1.8)a
Not obliterative bronchiolitis 37 (1.1)
Obliterative bronchiolitis 22 (0.7)
COPD with A1ATD 61 (1.9)
Sarcoidosis 54 (1.7)
Bronchiectasis 30 (0.9)
Obliterative bronchiolitis (not retransplant) 24 (0.7)
Other 96 (3.0)
A1ATD, α1-antitrypsin deficiency; COPD, chronic obstructive pulmon-
ary disease
aCombined retransplant data.
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Centers and transplant activity
The Registry now contains data from 3,677 adult recipients
who underwent heart-lung transplantation (includes retrans-
plantation) before 2012 (Figure 19). Twenty-nine participating
centers reported 63 adult heart-lung transplants performed in
2011. After a rapid rise in the 1980s and a peak at the end of
that decade, an overall decline in reported heart-lung transplants
occurred throughout the 1990s and into the first few years of
the next decade. However, the number of reported adult heart-
lung transplant procedures plateaued during the most recent
decade and ranged from 63 to 103 transplants per year. As
determined from transplants performed between January 2000
and June 2012, 36% of procedures occurred at the 7 centers
(7% of centers) that averaged between 4 and 9 procedures per
year, whereas 56% of the heart-lung transplant procedures
occurred at 87 centers (90% of centers) that averaged only 1 or
2 heart-lung transplants per year (Figure 20).
Donor age
Donors for adult heart-lung transplantation reported to the
Registry mainly consisted of adults, although some
adolescent and younger children also donated (Figure 21).
The Registry recorded a miniscule number of donors aged
4 65 years and a limited number aged 60 to 65 years.
Donors for adult heart-lung recipients during the first
6 months of 2012 were a median age of 38 years. Compared
with North American and European centers for the era of
January 2000 through June 2012, other centers located
throughout the world used a greater proportion of older and
pediatric donors (Figure 22).
Recipient age
Almost 66% of heart-lung transplant recipients are in the
group aged 18 to 49 years old (Figure 23). Few recipients
were aged 60 years or older. Since 1987, the median age of
recipients overall increased from 32 to 42 years (Figures 23
and 24). For transplants that occurred January 2000 through
June 2012, North American centers had a higher proportionof recipients aged 4 60 years than European and other
centers (Figure 25).
Donor and recipient age relationships
From January 1985 through June 2012, adult heart-lung
transplant recipients of all defined age groups received
organs from pediatric (mainly adolescent, ages 12–17 years)
donors (Figure 26). Few donors were aged 60 years or older.
As recipient age increased, the proportion with pediatric
donors decreased.
Indications
Sixty-three percent of the major indications for adult heart-
lung transplantation consisted of congenital heart disease
and IPAH (Table 5). For decades, the proportion of adult
transplants for diagnoses of congenital heart disease and
IPAH remained largely unchanged, while the proportion
decreased for CF and increased for acquired heart disease
(Figure 27). Significant geographic differences in major
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Figure 15 Adult lung transplant recipient age and hazard ratio
for mortality. Mortality models used patient cohorts from different
eras. The p-value is from the Cox proportional hazard multivariate
model that included age as an independent predictor, after
adjusting for other predictor variables.
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Figure 16 Adult lung transplant recipient center volume and
hazard ratio for 1-year mortality (transplants: January 1999–June
2011). The p-value is from the Cox proportional hazard multi-
variate model that included center volume as an independent
predictor, after adjusting for other predictor variables. The dashed
lines represent the 95% confidence intervals.
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lization discharge and 1-year follow-up, stratified by age
(transplant follow-ups: July 2004–June 2012).
0
20
40
60
80
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
%
 F
re
e 
fr
om
 B
ro
nc
hi
ol
iti
s
O
bl
ite
ra
ns
 S
yn
dr
om
e
Years
N at risk = 40 
N at risk at 5 years = 2,614 
N = 16,312
Figure 18 Adult lung transplant recipient freedom from
bronchiolitis obliterans syndrome (BOS), conditional on survival
to 14 days (transplant follow-ups: April 1994–June 2012). The
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2012, congenital heart disease represented the leading diagnosis
in all geographic locations (highest in North America). North
American centers had a lower frequency of transplant for CF
compared with European and other centers.0
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Survival
Figure 29 presents overall survival for 3,620 heart-lung
transplants performed between January 1982 and June 2011.
Compared with lung-only transplantation, heart-lung trans-
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Figure 22 Adult heart-lung transplant donor age distribution
by location (transplants: January 2000–June 2012). Each bar
represents the proportion of transplants for donor age categories
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Figure 21 Age distribution of heart-lung donors for adult
recipients by year of transplantation (transplants: January 1987–
June 2012). Bars represent proportion of transplants for donor age
categories within a given year, and the diamonds show the median
donor age.
Figure 23 Adult heart-lung recipient age by year (adult heart-
lung transplants: January 1987–June 2012). Each bar repre-
sents the proportion of transplants for recipient age categories
within a given year, and the diamonds show the median
recipient age.
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by location (transplants: January 2000–June 2012). Each bar
represents the proportion of transplants for recipient age categories
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Yusen et al. ISHLT 30th Adult Lung and Heart-Lung Transplant Report 975better long-term survival. Heart-lung transplant recipients
had survival rates of 71% at 3 months, 63% at 1 year, 51%
at 3 years, 44% at 5 years, and 31% at 10 years. Recipients
who survived the first year had a median survival of
10.0 years.Survival showed improvement for successive eras within
the time frame of January 1982 through June 2011
(Figure 30). Most of the improvement in survival occurred
in the early post-transplant period. Survival and 1-year
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Figure 27 Adult heart-lung transplant major indications by
year. Each colored area over each year represents the proportion of
transplants reported for each indication. A1ATD, α1-antitrypsin
deficiency; CF, cystic fibrosis; COPD, chronic obstructive
pulmonary disease; IPAH, idiopathic pulmonary arterial hyperten-
sion.
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Figure 29 Adult heart-lung transplant Kaplan-Meier survival
(transplants: January 1982–June 2011). Conditional, median survival
for the sub-set of recipients who were alive 1 year after transplantation.
The dashed lines represent the 95% confidence intervals.
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Figure 30 Adult heart-lung transplant Kaplan-Meier survival by
era (transplants: January 1982–June 2011). Conditional, median survival
for the sub-set of recipients who were alive 1 year after transplantation.
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The Journal of Heart and Lung Transplantation, Vol 32, No 10, October 2013976conditional survival did not differ according to pre-
transplantation diagnosis.2 Younger recipient age groups
tended to have longer survival than older groups
(Figure 31). A multivariable analysis of risk factors for
1-year mortality (Table 6) showed donor age was a
significant independent predictor, although it did not
demonstrate recipient age as a predictor.0%
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Figure 28 Adult heart-lung transplant diagnosis distribution by
location (transplants: January 2000–June 2012). Each bar repre-
sents the proportion of transplants for recipient diagnosis
(indication for transplantation) categories within a given location.
Figure 31 Adult heart-lung transplant Kaplan-Meier survival
by age group (transplants: January 1990–June 2011).
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Figure 32 Adult heart-lung transplant freedom from coronary
artery vasculopathy (CAV) and bronchiolitis obliterans syndrome
(adult heart-lung follow-ups: April 1994–June 2012).
Table 6 Risk Factors From Time of Transplant for 1-Year
Mortality in Adult Heart-Lung Transplant Recipients (Trans-
plants: January 1995–June 2011; N ¼ 1,681)
Variable No. HR (95% CI)a p-valuea
Diagnosis: IPAH vs. otherb 446 0.78
(0.63– 0.96)
0.0171
Donor age 0.0195
Transplant center volume
(borderline significant)
0.0519
CI, confidence interval; HR, hazard ratio; IPAH, idiopathic pulmonary
arterial hypertension.
aCalculated using Cox proportional hazard model.
bAll diagnoses other than IPAH and congenital.
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For heart-lung transplant recipients, based on reported
deaths between January 1992 and June 2012, the mostTable 7 Causes of Deaths for Adult Heart-Lung Recipients (Deaths:
0–30 days 31 days–1 year
(n ¼ 415) (n ¼ 322)
Cause of deatha No. (%)a No. (%)a
Bronchiolitis 0 13 (4.0)
Acute rejection 7 (1.7) 9 (2.8)
Malignancy
Lymphoma 0 8 (2.5)
Other 1 (0.2) 7 (2.2)
Infection
CMV 0 2 (0.6)
Non-CMV 74 (17.8) 113 (35.1)
Graft failure 112 (27.0) 68 (21.1)
Cardiovascular 32 (7.7) 14 (4.3)
Technical 91 (21.9) 9 (2.8)
Other 98 (23.6) 79 (24.5)
CMV, cytomegalovirus.
aPercentages refer to deaths in the respective time period.
bSome misclassification may occur among the cause of death terms of bronchio
reporting, may represent acute rejection, primary graft dysfunction, or other cau
or other causes late after transplant.
Table 8 Cumulative Morbidity Rates in Adult Heart-Lung Transplant S
1994–June 2012)
Outcome
Within 1 Year Total with k
(%) (No.)
Hypertension 59.1 421
Renal dysfunction 18.2 466
Abnormal creatinine o 2.5 mg/dl 11.2
Creatinine 4 2.5 mg/dl 2.8
Chronic dialysis 4.1
Renal transplant 0.2
Hyperlipidemia 26.6 443
Diabetes 18.8 469
Coronary artery vasculopathy 3.0 371
Bronchiolitis obliterans syndrome 8.6 441common identifiable causes of death in the first 30 days
post-transplant were graft failure, technical complications,
and non-CMV infections (Table 7). After the first year,
BOS/late graft failure and non-CMV infections became the
most common causes of death. Cardiovascular causes of
death accounted for a smaller but important proportion of
the deaths.Heart-lung rejection
BOS occurred more commonly than coronary artery
vasculopathy (CAV) at all time points, as determined from
follow-up data from April 1994 to June 2012 (Figure 32). At
1, 3, 5, and 10 years after heart-lung transplantation, 9%,
29%, 42%, and 59% of recipients developed BOS compared
with 3%, 7%, 10%, and 30% who developed CAV,
respectively.January 1992–June 2012)
41–3 years 43–5 years 45 years
(n ¼ 263) (n ¼ 163) (n ¼ 426)
No. (%)a No. (%)a No. (%)a
64 (24.3) 36 (22.1) 92 (21.6)
5 (1.9) 2 (1.2) 3 (0.7)
13 (4.9) 8 (4.9) 9 (2.1)
12 (4.6) 5 (3.1) 27 (6.3)
1 (0.4) 1 (0.6) 1 (0.2)
75 (28.5) 42 (25.8) 102 (23.9)
36 (13.7) 29 (17.8) 59 (13.8)
19 (7.2) 16 (9.8) 37 (8.7)
3 (1.1) 3 (1.8) 3 (0.7)
35 (13.3) 21 (12.9) 93 (21.8)
litis, acute rejection, and graft failure. Graft failure, due to variation in
ses early after transplant, or bronchiolitis obliterans syndrome of the lung
urvivors Within 1 and 5 Years After Transplant (Follow-ups: April
nown response Within 5 Years Total with known response
(%) (No.)
87.8 148
45.3 181
31.5
10.5
2.2
1.1
69.2 156
27.9 179
7.6 92
28.3 152
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Morbidities often associated with immunosuppressive
therapy commonly occurred at both the 1-year and 5-year
time points after heart-lung transplantation, and their rates
increased over time (Table 8). Of all malignancies,
lymphoma had the highest incidence until about 9 years
after transplant, and the highest event rate occurred during
the first post-transplant year.2
Conclusions
On the basis of Registry reporting, international lung
transplantation rates showed continued growth, whereas
heart-lung transplantation rates plateaued. Survival for both
transplant types improved over time, mainly due to
improved survival in the early post-transplant period.
Morbidities after lung and heart-lung transplantation
frequently occurred, and the main long-term contributors
to decreased long-term survival consisted of BOS of thelung and infections. Older donor age showed an association
with decreased survival for both transplant types. Recipient
age for both transplant types increased over time, and older
sub-groups generally had lower long-term survival and
higher long-term complication rates than younger sub-
groups. However, older recipients had similar short-term
survival compared with younger recipients.
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